Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript

Group 1 - The company reported an organic decline of 1% in the first quarter, indicating a challenging macro environment [1] - Large pharma, which constitutes about 30% of the company's revenue, has shown strong performance with double-digit growth for three consecutive quarters [1] - The company is optimistic about the Chinese market, having experienced organic growth for two consecutive quarters and expecting continued growth in the upcoming quarter [2]